Download PDF
Ernährung & Medizin 2008; 23(3): 144-148
DOI: 10.1055/s-2008-1081376
VFED Wissen
© Hippokrates Verlag in MVS Medizinverlage Stuttgart GmbH & Co. KG

Wann sind Triglyzeride ein wichtiger Risikofaktor für die koronare Herzkrankheit?

Werner O. Richter
Further Information

Publication History

Publication Date:
03 September 2008 (online)

    Permissions and Reprints

Bestimmte Fettstoffwechselstörungen sind ein wichtiger Risikofaktor für das vorzeitige Entstehen oder das Fortschreiten der Atherosklerose, insbesondere an den Koronararterien. In Abhängigkeit von der Schwere der Fettstoffwechselstörung, die sich nicht an der Höhe der Konzentration von Cholesterin oder Triglyzeriden im Blut festmachen lässt, von ihrer Dauer und von dem Vorhandensein anderer Risikofaktoren, nimmt die Gefahr für die Entwicklung der Atherosklerose zu. Die richtige Risikobeurteilung erfordert daher die sorgfältige Diagnose der Fettstoffwechselstörung und die Evaluation anderer kardiovaskulärer Risikofaktoren, wie Zigarettenrauchen oder Bluthochdruck. Wie lange die Fettstoffwechselstörung schon bestanden hat, ist in vielen Fällen schwer zu beurteilen.

Für die Risikobeurteilung erfordern die Diagnostik und Therapie der Hypertriglyzeridämie ein besonderes Wissen.

Weiterführende Literatur

  • 1 Austin M A, Brunzell J D, Fitch W L, Krauss R M. Inheritance of low density lipoprotein subclass patterns in familial combined hyperlipidemia.  Arteriosclerosis. 1990;  10 520-530
    PubMedGoogle Scholar
  • 2 Austin M A, Hokanson J E, Edwards K L. Hypertriglyceridemia as a cardiovascular risk factor.  Am J Cardiol. 1998;  81 7B-12B
    CrossrefPubMedGoogle Scholar
  • 3 Ayyobi A F, McGladdery S H, McNeely M J. et al . Small, dense LDL and elevated apolipoprotein B are the common characteristics for the three major lipid phenotypes of familial combined hyperlipidemia.  Arterioscler Thromb Vasc Biol. 2003;  23 1289-1294
    CrossrefPubMedGoogle Scholar
  • 4 Bach A C, Ingenbleek Y, Frey A. The usefulness of dietary medium-chain triglycerides in body weight control: fact or fancy?.  J Lipid Res. 1997;  37 708-726
    PubMedGoogle Scholar
  • 5 Bansal S, Buring J E, Rifai N. et al . Fasting compared with nonfasting triglycerides and risk of coronary events in women.  JAMA. 2007;  298 309-316
    CrossrefPubMedGoogle Scholar
  • 6 Brunzell J D, Albers J J, Chait A. et al . Plasma lipoproteins in familial combined hyperlipidemia and monogenic familial hypertriglyceridemia.  J Lipid Res. 1983;  24 147-155
    PubMedGoogle Scholar
  • 7 Brunzell J D. Clinical practice. Hypertriglyceridemia.  N Engl J Med. 2007;  357 1009-1017
    CrossrefPubMedGoogle Scholar
  • 8 Calabresi L, Donati D, Pazzucconi F. et al . Omacor in familial combined hyperlipidemia: effects on lipids and low density lipoprotein subclasses.  Atherosclerosis. 2000;  148 387-396
    CrossrefPubMedGoogle Scholar
  • 9 Chajek-Shaul T, Berry E M, Ziv E. et al . Smoking depresses adipose lipoprotein lipase response to oral glucose.  Eur J Clin Invest. 1990;  20 299-304
    CrossrefPubMedGoogle Scholar
  • 10 DAIS Study Group: Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: The Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001 357: 905-910
    Google Scholar
  • 11 de Lany J P, Windhauser M M, Champagne C M, Bray G A. Differential oxidation of individual fatty acids in humans.  Am J Clin Nutr. 2000;  72 905-911
    PubMedGoogle Scholar
  • 12 Eberly L E, Stamler J, Neaton J D. Relation of triglyceride levels, fasting and nonfasting, to fatal and nonfatal coronary heart disease.  Arch Intern Med. 2003;  163 1077-1083
    CrossrefPubMedGoogle Scholar
  • 13 Genest Jr. J J, Martin-Munley S S, McNamara J R. et al . Familial lipoprotein disorders in patients with premature coronary artery disease.  Circulation. 1992;  85 2025-2033
    PubMedGoogle Scholar
  • 14 Georgieva A M, van Greevenbrock M M, Krauss R M. et al . Subclasses of low-density lipoprotein and very low-density lipoprotein in familial combined hyperlipidemia: relationship to multiple lipoprotein phenotype.  Arterioscler Thromb Vasc Biol. 2004;  24 744-749
    CrossrefPubMedGoogle Scholar
  • 15 Grundy S M, Cleeman J I, Merz C N. et al . Implications of recent clinical trials for the National Cholesterol Education Program Treatment Panel III Guidelines.  Circulation. 2004;  110 227-229
    CrossrefPubMedGoogle Scholar
  • 16 Grunnet N, Kondrup J. The effect of ethanol on the beta-oxidation of fatty acids.  Alcohol Clin Exp Res. 1986;  10 (Suppl.) 64S-68S
    CrossrefPubMedGoogle Scholar
  • 17 Harris W S. n-3 fatty acids and lipoproteins: comparison of results from human and animal studies.  Lipids. 1996;  31 243-252
    CrossrefPubMedGoogle Scholar
  • 18 Hokanson J E, Austin M A, Zambon A, Brunzell J D. Plasma triglyceride and LDL heterogeneity in familial combined hyperlipidemia.  Arterioscler Thromb. 1993;  13 427-433
    PubMedGoogle Scholar
  • 19 Hokanson J E, Austin M A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies.  J Cardiovasc Rsik. 1996;  3 213-219
    CrossrefPubMedGoogle Scholar
  • 20 Hopkins P H, Heiss G, Ellison R C. et al . Coronary artery disease in familial combined hyperlipidemia and familial hypertriglyceridemia: a case-control comparison from the National Heart, Lung and Blood Institute Family Heart Study.  Circulation. 2003;  108 519-523
    CrossrefPubMedGoogle Scholar
  • 21 Howard B V. Insulin resistance and lipid metabolism.  Am J Cardiol. 1999;  84 28J-32J
    PubMedGoogle Scholar
  • 22 Jeppesen J, Hein H O, Suadicani P, Gyntelberg F. Triglyceride concentration and ischemic heart disease: an eight-year follow-up in the Copenhagen Male Study.  Circulation. 1999;  97 1029-1036
    PubMedGoogle Scholar
  • 23 Keech A, Simes RJ Barter P. et al . Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study).  Lancet. 2005;  366 1849-1861
    CrossrefPubMedGoogle Scholar
  • 24 Lefebvre A M, Peinado-Onsurbe J, Leitersdorf I. et al . Regulation of lipoprotein metabolism by thiazolidindiones occurs through a distinct but complementary mechanism relative to fibrates.  Arterioscler Thromb Vasc Biol. 1997;  17 1756-1764
    PubMedGoogle Scholar
  • 25 Martin G, Schoonjans K, Lefebvre A M. et al . Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARa and PPARg activators.  J Biol Chem. 1997;  272 28 210-28 217
    PubMedGoogle Scholar
  • 26 Mensink R P, Zock P L, Kester A D, Katan M B. Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials.  Am J Clin Nutr. 2003;  77 146-1155
    PubMedGoogle Scholar
  • 27 Miller M, Seidler A, Moalemi A, Pearson T A. Normal triglyceride levels and coronary artery disease events: the Baltimore Coronary Observational Long-Term Study.  J Am Coll Cardiol. 1998;  31 1252-1257
    CrossrefPubMedGoogle Scholar
  • 28 Mittendorfer B, Sidossis L S. Mechanism for the increase in plasma triacylglycerol concentrations after consumption of short-term, high-carbohydrate diets.  Am J Clin Nutr. 2001;  73 892-899
    PubMedGoogle Scholar
  • 29 Montori V M, Farmer A, Wollan P C, Dinneen S F. Fish oil supplementation in type 2 diabetes.  Diabetes Care. 2000;  23 1407-1415
    CrossrefPubMedGoogle Scholar
  • 30 Nordestgaard B G, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women.  JAMA. 2007;  298 299-308
    CrossrefPubMedGoogle Scholar
  • 31 Otvos J D, Collins D, Freedman D S. et al . Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial.  Circulation. 2006;  113 1556-1563
    CrossrefPubMedGoogle Scholar
  • 32 Pschierer V, Richter W O, Schwandt P. Primary chylomicronemia in patients with severe familial hypertriglyceridemia responds to long-term treatment with n-3 fatty acids.  J Nutr. 1995;  125 1490-1495
    PubMedGoogle Scholar
  • 33 Richter W O, Schwandt P. Medikamentöse Therapie von Fettstoffwechselstörungen. In: Schwandt P, Richter WO, Parhofer KG Handbuch der Fettstoffwechselstörungen. Stuttgart, New York; Schattauer 2001: 436-527
    Google Scholar
  • 34 Richter W O, Eckardstein von A. Fettstoffwechsel. In: Siegenthaler W, Blum H, Hrsg Klinische Pathophysiologie. 9. Aufl Stuttgart; Thieme 2006
    Google Scholar
  • 35 Richter W O. Chylomicronemia and chylomicronemia syndrome. In: Gotto AM, Mancini M, Richter WO, Schwandt P, eds Treatment of Severe Dyslipoproteinemia in the Prevention of Coronary Heart Disease 3. Basel; Karger 1992: 164-173
    Google Scholar
  • 36 Rubins H B, Robins S J, Collins D. et al . Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol.  N Engl J Med. 1999;  341 410-418
    CrossrefPubMedGoogle Scholar
  • 37 Savolainen M J, Baroana E, Leo M A, Lieber C S. Pathogenesis of the hypertriglyceridemia at early stages of alcoholic liver injury in the baboon.  J Lipid Res. 1986;  27 1073-1089
    PubMedGoogle Scholar
  • 38 Schoonjans K, Watanabe M, Suzuki H. et al . Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferator response element in the C promoter.  J Biol Chem. 1995;  270 19 269-19 276
    PubMedGoogle Scholar
  • 39 Semenkovich C F. Insulin resistance and atherosclerosis.  J Clin Invest. 2006;  116 1813-1822
    CrossrefPubMedGoogle Scholar
  • 40 Smelt A H, de Beer F. Apolipoprotein E and familial dysbetalipoproteinemia: clinical, biochemical, and genetic aspects.  Semin Vasc Med. 2004;  4 249-257
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Välimäki M, Taskinen M R, Ylikahri R. et al . Comparison of the effects of two different doses of alcohol on serum lipoproteins, HDL-subfractions and apolipoproteins A-I and A-II: a controlled study.  Eur J Clin Invest. 1988;  18 472-480
    CrossrefPubMedGoogle Scholar
  • 42 Zambon A, Brown B G, Deeb S S, Brunzell J D. Genetics of apolipoprotein B and apolipoprotein A-I and premature coronary artery disease.  J Intern Med. 2006;  259 473-480
    CrossrefPubMedGoogle Scholar

Prof. Dr. Werner O. Richter

Institut für Fettstoffwechsel und Hämorheologie

Blumenstraße 6

86949 Windach

      >